nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—CYP2D6—Alzheimer's disease	0.13	1	CbGaD
Sorafenib—CYP2B6—Memantine—Alzheimer's disease	0.0652	0.205	CbGbCtD
Sorafenib—CYP2D6—Rivastigmine—Alzheimer's disease	0.0454	0.143	CbGbCtD
Sorafenib—CYP2C19—Memantine—Alzheimer's disease	0.0414	0.13	CbGbCtD
Sorafenib—CYP2C9—Donepezil—Alzheimer's disease	0.0397	0.125	CbGbCtD
Sorafenib—CYP2D6—Donepezil—Alzheimer's disease	0.0363	0.114	CbGbCtD
Sorafenib—CYP3A4—Rivastigmine—Alzheimer's disease	0.0289	0.0908	CbGbCtD
Sorafenib—CYP2D6—Galantamine—Alzheimer's disease	0.0234	0.0735	CbGbCtD
Sorafenib—CYP3A4—Donepezil—Alzheimer's disease	0.0231	0.0725	CbGbCtD
Sorafenib—CYP3A4—Galantamine—Alzheimer's disease	0.0149	0.0468	CbGbCtD
Sorafenib—HTR2C—choroid plexus—Alzheimer's disease	0.00696	0.0567	CbGeAlD
Sorafenib—CDKL2—forebrain—Alzheimer's disease	0.00323	0.0263	CbGeAlD
Sorafenib—CDKL2—telencephalon—Alzheimer's disease	0.00297	0.0242	CbGeAlD
Sorafenib—TIE1—blood vessel—Alzheimer's disease	0.00254	0.0207	CbGeAlD
Sorafenib—MUSK—nervous system—Alzheimer's disease	0.00215	0.0175	CbGeAlD
Sorafenib—FLT4—blood vessel—Alzheimer's disease	0.0021	0.0171	CbGeAlD
Sorafenib—HTR2C—telencephalic ventricle—Alzheimer's disease	0.00204	0.0166	CbGeAlD
Sorafenib—CDKL2—nervous system—Alzheimer's disease	0.00176	0.0143	CbGeAlD
Sorafenib—CDKL2—central nervous system—Alzheimer's disease	0.00169	0.0138	CbGeAlD
Sorafenib—FLT1—blood vessel—Alzheimer's disease	0.00164	0.0133	CbGeAlD
Sorafenib—MAPK11—telencephalon—Alzheimer's disease	0.00159	0.0129	CbGeAlD
Sorafenib—MAPK15—nervous system—Alzheimer's disease	0.00158	0.0129	CbGeAlD
Sorafenib—MAPK15—central nervous system—Alzheimer's disease	0.00152	0.0124	CbGeAlD
Sorafenib—CDKL3—brain—Alzheimer's disease	0.00147	0.012	CbGeAlD
Sorafenib—KDR—blood vessel—Alzheimer's disease	0.00138	0.0113	CbGeAlD
Sorafenib—CDKL2—brain—Alzheimer's disease	0.00134	0.0109	CbGeAlD
Sorafenib—FLT4—embryo—Alzheimer's disease	0.00125	0.0102	CbGeAlD
Sorafenib—KIT—blood vessel—Alzheimer's disease	0.00122	0.00998	CbGeAlD
Sorafenib—MAPK15—brain—Alzheimer's disease	0.00121	0.00984	CbGeAlD
Sorafenib—PDGFRB—blood vessel—Alzheimer's disease	0.0012	0.00975	CbGeAlD
Sorafenib—RET—embryo—Alzheimer's disease	0.00111	0.00902	CbGeAlD
Sorafenib—FGFR1—telencephalon—Alzheimer's disease	0.00101	0.0082	CbGeAlD
Sorafenib—FLT1—embryo—Alzheimer's disease	0.000975	0.00795	CbGeAlD
Sorafenib—RAF1—embryo—Alzheimer's disease	0.00097	0.0079	CbGeAlD
Sorafenib—MAP3K7—telencephalon—Alzheimer's disease	0.000953	0.00776	CbGeAlD
Sorafenib—MAPK11—nervous system—Alzheimer's disease	0.000937	0.00764	CbGeAlD
Sorafenib—MKNK2—telencephalon—Alzheimer's disease	0.000923	0.00752	CbGeAlD
Sorafenib—CDK7—nervous system—Alzheimer's disease	0.000922	0.00751	CbGeAlD
Sorafenib—PDGFRA—embryo—Alzheimer's disease	0.000914	0.00745	CbGeAlD
Sorafenib—MKNK1—telencephalon—Alzheimer's disease	0.000912	0.00743	CbGeAlD
Sorafenib—AURKC—nervous system—Alzheimer's disease	0.000908	0.0074	CbGeAlD
Sorafenib—RALBP1—forebrain—Alzheimer's disease	0.000907	0.00739	CbGeAlD
Sorafenib—MAPK11—central nervous system—Alzheimer's disease	0.000902	0.00735	CbGeAlD
Sorafenib—CDK7—central nervous system—Alzheimer's disease	0.000888	0.00723	CbGeAlD
Sorafenib—MAPK11—cerebellum—Alzheimer's disease	0.000882	0.00719	CbGeAlD
Sorafenib—AURKC—central nervous system—Alzheimer's disease	0.000874	0.00712	CbGeAlD
Sorafenib—CDK7—cerebellum—Alzheimer's disease	0.000868	0.00707	CbGeAlD
Sorafenib—TAOK2—cerebellum—Alzheimer's disease	0.000861	0.00701	CbGeAlD
Sorafenib—RAF1—forebrain—Alzheimer's disease	0.000858	0.00699	CbGeAlD
Sorafenib—EPHB6—forebrain—Alzheimer's disease	0.000853	0.00695	CbGeAlD
Sorafenib—EPHA6—nervous system—Alzheimer's disease	0.000841	0.00685	CbGeAlD
Sorafenib—RALBP1—telencephalon—Alzheimer's disease	0.000834	0.00679	CbGeAlD
Sorafenib—KDR—embryo—Alzheimer's disease	0.000824	0.00672	CbGeAlD
Sorafenib—HIPK4—brain—Alzheimer's disease	0.000813	0.00662	CbGeAlD
Sorafenib—EPHA6—central nervous system—Alzheimer's disease	0.000809	0.00659	CbGeAlD
Sorafenib—PDGFRA—forebrain—Alzheimer's disease	0.000808	0.00659	CbGeAlD
Sorafenib—CSF1R—embryo—Alzheimer's disease	0.000805	0.00656	CbGeAlD
Sorafenib—ZAK—nervous system—Alzheimer's disease	0.000797	0.00649	CbGeAlD
Sorafenib—FLT1—telencephalon—Alzheimer's disease	0.000793	0.00646	CbGeAlD
Sorafenib—RAF1—telencephalon—Alzheimer's disease	0.000789	0.00642	CbGeAlD
Sorafenib—EPHB6—telencephalon—Alzheimer's disease	0.000784	0.00639	CbGeAlD
Sorafenib—ZAK—central nervous system—Alzheimer's disease	0.000767	0.00625	CbGeAlD
Sorafenib—MAP3K19—nervous system—Alzheimer's disease	0.000764	0.00622	CbGeAlD
Sorafenib—ZAK—cerebellum—Alzheimer's disease	0.00075	0.00611	CbGeAlD
Sorafenib—PDGFRA—telencephalon—Alzheimer's disease	0.000743	0.00606	CbGeAlD
Sorafenib—MAP3K19—central nervous system—Alzheimer's disease	0.000736	0.00599	CbGeAlD
Sorafenib—HIPK3—cerebellum—Alzheimer's disease	0.000734	0.00598	CbGeAlD
Sorafenib—KIT—embryo—Alzheimer's disease	0.000731	0.00595	CbGeAlD
Sorafenib—KDR—forebrain—Alzheimer's disease	0.000729	0.00594	CbGeAlD
Sorafenib—TIE1—nervous system—Alzheimer's disease	0.000729	0.00594	CbGeAlD
Sorafenib—MAPK11—brain—Alzheimer's disease	0.000716	0.00584	CbGeAlD
Sorafenib—PDGFRB—embryo—Alzheimer's disease	0.000714	0.00581	CbGeAlD
Sorafenib—CSF1R—forebrain—Alzheimer's disease	0.000712	0.0058	CbGeAlD
Sorafenib—CDK7—brain—Alzheimer's disease	0.000705	0.00574	CbGeAlD
Sorafenib—TIE1—central nervous system—Alzheimer's disease	0.000702	0.00572	CbGeAlD
Sorafenib—TAOK2—brain—Alzheimer's disease	0.000699	0.0057	CbGeAlD
Sorafenib—AURKC—brain—Alzheimer's disease	0.000694	0.00565	CbGeAlD
Sorafenib—TIE1—cerebellum—Alzheimer's disease	0.000686	0.00559	CbGeAlD
Sorafenib—MAP2K5—telencephalon—Alzheimer's disease	0.000671	0.00546	CbGeAlD
Sorafenib—BRAF—cerebellum—Alzheimer's disease	0.000658	0.00536	CbGeAlD
Sorafenib—CSF1R—telencephalon—Alzheimer's disease	0.000654	0.00533	CbGeAlD
Sorafenib—EPHA6—brain—Alzheimer's disease	0.000643	0.00523	CbGeAlD
Sorafenib—EPHX2—cerebellum—Alzheimer's disease	0.000628	0.00512	CbGeAlD
Sorafenib—FLT3—cerebellum—Alzheimer's disease	0.000624	0.00508	CbGeAlD
Sorafenib—ZAK—brain—Alzheimer's disease	0.000609	0.00496	CbGeAlD
Sorafenib—HIPK3—brain—Alzheimer's disease	0.000596	0.00486	CbGeAlD
Sorafenib—KIT—telencephalon—Alzheimer's disease	0.000594	0.00484	CbGeAlD
Sorafenib—MAP3K19—brain—Alzheimer's disease	0.000584	0.00476	CbGeAlD
Sorafenib—PDGFRB—telencephalon—Alzheimer's disease	0.00058	0.00473	CbGeAlD
Sorafenib—FGFR1—cerebellum—Alzheimer's disease	0.000559	0.00456	CbGeAlD
Sorafenib—TIE1—brain—Alzheimer's disease	0.000557	0.00454	CbGeAlD
Sorafenib—MKNK2—nervous system—Alzheimer's disease	0.000545	0.00444	CbGeAlD
Sorafenib—Tinnitus—Galantamine—Alzheimer's disease	0.00054	0.00255	CcSEcCtD
Sorafenib—Dry skin—Memantine—Alzheimer's disease	0.00054	0.00255	CcSEcCtD
Sorafenib—MKNK1—nervous system—Alzheimer's disease	0.000538	0.00439	CbGeAlD
Sorafenib—Abdominal discomfort—Donepezil—Alzheimer's disease	0.000537	0.00253	CcSEcCtD
Sorafenib—Flushing—Galantamine—Alzheimer's disease	0.000537	0.00253	CcSEcCtD
Sorafenib—Cardiac disorder—Galantamine—Alzheimer's disease	0.000537	0.00253	CcSEcCtD
Sorafenib—Hypokalaemia—Memantine—Alzheimer's disease	0.000536	0.00253	CcSEcCtD
Sorafenib—Dehydration—Rivastigmine—Alzheimer's disease	0.000536	0.00253	CcSEcCtD
Sorafenib—BRAF—brain—Alzheimer's disease	0.000534	0.00435	CbGeAlD
Sorafenib—HTR2C—forebrain—Alzheimer's disease	0.000532	0.00434	CbGeAlD
Sorafenib—RET—nervous system—Alzheimer's disease	0.000532	0.00433	CbGeAlD
Sorafenib—Aspartate aminotransferase increased—Memantine—Alzheimer's disease	0.00053	0.0025	CcSEcCtD
Sorafenib—MAP3K7—cerebellum—Alzheimer's disease	0.000529	0.00431	CbGeAlD
Sorafenib—Dry skin—Rivastigmine—Alzheimer's disease	0.000528	0.00249	CcSEcCtD
Sorafenib—Nasopharyngitis—Memantine—Alzheimer's disease	0.000526	0.00248	CcSEcCtD
Sorafenib—Abdominal pain upper—Rivastigmine—Alzheimer's disease	0.000526	0.00248	CcSEcCtD
Sorafenib—Angiopathy—Galantamine—Alzheimer's disease	0.000525	0.00248	CcSEcCtD
Sorafenib—MKNK2—central nervous system—Alzheimer's disease	0.000525	0.00428	CbGeAlD
Sorafenib—Hypokalaemia—Rivastigmine—Alzheimer's disease	0.000524	0.00247	CcSEcCtD
Sorafenib—Immune system disorder—Galantamine—Alzheimer's disease	0.000523	0.00247	CcSEcCtD
Sorafenib—Gastritis—Memantine—Alzheimer's disease	0.000521	0.00246	CcSEcCtD
Sorafenib—Breast disorder—Rivastigmine—Alzheimer's disease	0.00052	0.00246	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Memantine—Alzheimer's disease	0.000519	0.00245	CcSEcCtD
Sorafenib—MKNK1—central nervous system—Alzheimer's disease	0.000518	0.00422	CbGeAlD
Sorafenib—Arrhythmia—Galantamine—Alzheimer's disease	0.000517	0.00244	CcSEcCtD
Sorafenib—Nasopharyngitis—Rivastigmine—Alzheimer's disease	0.000515	0.00243	CcSEcCtD
Sorafenib—MKNK2—cerebellum—Alzheimer's disease	0.000513	0.00418	CbGeAlD
Sorafenib—RET—central nervous system—Alzheimer's disease	0.000512	0.00417	CbGeAlD
Sorafenib—EPHX2—brain—Alzheimer's disease	0.00051	0.00416	CbGeAlD
Sorafenib—Gastritis—Rivastigmine—Alzheimer's disease	0.00051	0.0024	CcSEcCtD
Sorafenib—Dysphagia—Memantine—Alzheimer's disease	0.000509	0.0024	CcSEcCtD
Sorafenib—Mental disorder—Galantamine—Alzheimer's disease	0.000507	0.00239	CcSEcCtD
Sorafenib—Weight decreased—Donepezil—Alzheimer's disease	0.000507	0.00239	CcSEcCtD
Sorafenib—MKNK1—cerebellum—Alzheimer's disease	0.000507	0.00413	CbGeAlD
Sorafenib—Malnutrition—Galantamine—Alzheimer's disease	0.000504	0.00238	CcSEcCtD
Sorafenib—ABCC4—forebrain—Alzheimer's disease	0.000503	0.00409	CbGeAlD
Sorafenib—Pneumonia—Donepezil—Alzheimer's disease	0.000502	0.00237	CcSEcCtD
Sorafenib—RET—cerebellum—Alzheimer's disease	0.0005	0.00408	CbGeAlD
Sorafenib—HTR2B—forebrain—Alzheimer's disease	0.0005	0.00407	CbGeAlD
Sorafenib—Infestation NOS—Donepezil—Alzheimer's disease	0.0005	0.00236	CcSEcCtD
Sorafenib—Infestation—Donepezil—Alzheimer's disease	0.0005	0.00236	CcSEcCtD
Sorafenib—Pancreatitis—Memantine—Alzheimer's disease	0.000499	0.00235	CcSEcCtD
Sorafenib—Dysphagia—Rivastigmine—Alzheimer's disease	0.000498	0.00235	CcSEcCtD
Sorafenib—Dysgeusia—Galantamine—Alzheimer's disease	0.000493	0.00233	CcSEcCtD
Sorafenib—Acute coronary syndrome—Donepezil—Alzheimer's disease	0.000492	0.00232	CcSEcCtD
Sorafenib—RALBP1—nervous system—Alzheimer's disease	0.000492	0.00401	CbGeAlD
Sorafenib—Renal failure—Donepezil—Alzheimer's disease	0.000491	0.00232	CcSEcCtD
Sorafenib—Myocardial infarction—Donepezil—Alzheimer's disease	0.00049	0.00231	CcSEcCtD
Sorafenib—HTR2C—telencephalon—Alzheimer's disease	0.000489	0.00399	CbGeAlD
Sorafenib—Pancreatitis—Rivastigmine—Alzheimer's disease	0.000488	0.0023	CcSEcCtD
Sorafenib—Jaundice—Donepezil—Alzheimer's disease	0.000487	0.0023	CcSEcCtD
Sorafenib—Muscle spasms—Galantamine—Alzheimer's disease	0.000484	0.00229	CcSEcCtD
Sorafenib—Neutropenia—Memantine—Alzheimer's disease	0.000476	0.00224	CcSEcCtD
Sorafenib—RALBP1—central nervous system—Alzheimer's disease	0.000474	0.00386	CbGeAlD
Sorafenib—Epistaxis—Donepezil—Alzheimer's disease	0.000471	0.00222	CcSEcCtD
Sorafenib—Erectile dysfunction—Memantine—Alzheimer's disease	0.000469	0.00221	CcSEcCtD
Sorafenib—FLT1—nervous system—Alzheimer's disease	0.000468	0.00382	CbGeAlD
Sorafenib—Anaemia—Galantamine—Alzheimer's disease	0.000466	0.0022	CcSEcCtD
Sorafenib—RAF1—nervous system—Alzheimer's disease	0.000466	0.00379	CbGeAlD
Sorafenib—RALBP1—cerebellum—Alzheimer's disease	0.000463	0.00377	CbGeAlD
Sorafenib—EPHB6—nervous system—Alzheimer's disease	0.000463	0.00377	CbGeAlD
Sorafenib—FLT4—brain—Alzheimer's disease	0.00046	0.00375	CbGeAlD
Sorafenib—Weight decreased—Memantine—Alzheimer's disease	0.00046	0.00217	CcSEcCtD
Sorafenib—HTR2B—telencephalon—Alzheimer's disease	0.00046	0.00374	CbGeAlD
Sorafenib—Erectile dysfunction—Rivastigmine—Alzheimer's disease	0.000458	0.00216	CcSEcCtD
Sorafenib—Pneumonia—Memantine—Alzheimer's disease	0.000456	0.00215	CcSEcCtD
Sorafenib—FGFR1—brain—Alzheimer's disease	0.000454	0.0037	CbGeAlD
Sorafenib—Infestation NOS—Memantine—Alzheimer's disease	0.000454	0.00214	CcSEcCtD
Sorafenib—Infestation—Memantine—Alzheimer's disease	0.000454	0.00214	CcSEcCtD
Sorafenib—Syncope—Galantamine—Alzheimer's disease	0.000452	0.00213	CcSEcCtD
Sorafenib—FLT1—central nervous system—Alzheimer's disease	0.000451	0.00367	CbGeAlD
Sorafenib—Haemoglobin—Donepezil—Alzheimer's disease	0.000451	0.00213	CcSEcCtD
Sorafenib—Weight decreased—Rivastigmine—Alzheimer's disease	0.00045	0.00212	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Memantine—Alzheimer's disease	0.00045	0.00212	CcSEcCtD
Sorafenib—Haemorrhage—Donepezil—Alzheimer's disease	0.000448	0.00212	CcSEcCtD
Sorafenib—RAF1—central nervous system—Alzheimer's disease	0.000448	0.00365	CbGeAlD
Sorafenib—Acute coronary syndrome—Memantine—Alzheimer's disease	0.000447	0.00211	CcSEcCtD
Sorafenib—Pneumonia—Rivastigmine—Alzheimer's disease	0.000446	0.00211	CcSEcCtD
Sorafenib—Renal failure—Memantine—Alzheimer's disease	0.000446	0.0021	CcSEcCtD
Sorafenib—EPHB6—central nervous system—Alzheimer's disease	0.000446	0.00363	CbGeAlD
Sorafenib—Myocardial infarction—Memantine—Alzheimer's disease	0.000445	0.0021	CcSEcCtD
Sorafenib—Neuropathy peripheral—Memantine—Alzheimer's disease	0.000445	0.0021	CcSEcCtD
Sorafenib—Infestation—Rivastigmine—Alzheimer's disease	0.000444	0.00209	CcSEcCtD
Sorafenib—Infestation NOS—Rivastigmine—Alzheimer's disease	0.000444	0.00209	CcSEcCtD
Sorafenib—STK10—nervous system—Alzheimer's disease	0.000443	0.00361	CbGeAlD
Sorafenib—Urinary tract disorder—Donepezil—Alzheimer's disease	0.000443	0.00209	CcSEcCtD
Sorafenib—Loss of consciousness—Galantamine—Alzheimer's disease	0.000443	0.00209	CcSEcCtD
Sorafenib—FLT1—cerebellum—Alzheimer's disease	0.000441	0.00359	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Rivastigmine—Alzheimer's disease	0.00044	0.00208	CcSEcCtD
Sorafenib—Urethral disorder—Donepezil—Alzheimer's disease	0.00044	0.00207	CcSEcCtD
Sorafenib—Cough—Galantamine—Alzheimer's disease	0.00044	0.00207	CcSEcCtD
Sorafenib—PDGFRA—nervous system—Alzheimer's disease	0.000439	0.00358	CbGeAlD
Sorafenib—RAF1—cerebellum—Alzheimer's disease	0.000438	0.00357	CbGeAlD
Sorafenib—Acute coronary syndrome—Rivastigmine—Alzheimer's disease	0.000437	0.00206	CcSEcCtD
Sorafenib—Renal failure—Rivastigmine—Alzheimer's disease	0.000436	0.00206	CcSEcCtD
Sorafenib—EPHB6—cerebellum—Alzheimer's disease	0.000436	0.00355	CbGeAlD
Sorafenib—Neuropathy peripheral—Rivastigmine—Alzheimer's disease	0.000435	0.00205	CcSEcCtD
Sorafenib—Myocardial infarction—Rivastigmine—Alzheimer's disease	0.000435	0.00205	CcSEcCtD
Sorafenib—Hypertension—Galantamine—Alzheimer's disease	0.000435	0.00205	CcSEcCtD
Sorafenib—MAP3K7—brain—Alzheimer's disease	0.00043	0.0035	CbGeAlD
Sorafenib—Hepatobiliary disease—Memantine—Alzheimer's disease	0.000429	0.00202	CcSEcCtD
Sorafenib—Arthralgia—Galantamine—Alzheimer's disease	0.000429	0.00202	CcSEcCtD
Sorafenib—Myalgia—Galantamine—Alzheimer's disease	0.000429	0.00202	CcSEcCtD
Sorafenib—Epistaxis—Memantine—Alzheimer's disease	0.000428	0.00202	CcSEcCtD
Sorafenib—STK10—central nervous system—Alzheimer's disease	0.000427	0.00348	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Galantamine—Alzheimer's disease	0.000426	0.00201	CcSEcCtD
Sorafenib—PDGFRA—central nervous system—Alzheimer's disease	0.000422	0.00344	CbGeAlD
Sorafenib—Hepatobiliary disease—Rivastigmine—Alzheimer's disease	0.00042	0.00198	CcSEcCtD
Sorafenib—Dry mouth—Galantamine—Alzheimer's disease	0.000419	0.00198	CcSEcCtD
Sorafenib—Epistaxis—Rivastigmine—Alzheimer's disease	0.000419	0.00197	CcSEcCtD
Sorafenib—Tinnitus—Donepezil—Alzheimer's disease	0.000418	0.00197	CcSEcCtD
Sorafenib—STK10—cerebellum—Alzheimer's disease	0.000417	0.0034	CbGeAlD
Sorafenib—MKNK2—brain—Alzheimer's disease	0.000417	0.00339	CbGeAlD
Sorafenib—PDGFRA—cerebellum—Alzheimer's disease	0.000413	0.00336	CbGeAlD
Sorafenib—MKNK1—brain—Alzheimer's disease	0.000411	0.00335	CbGeAlD
Sorafenib—Haemoglobin—Memantine—Alzheimer's disease	0.000409	0.00193	CcSEcCtD
Sorafenib—Haemorrhage—Memantine—Alzheimer's disease	0.000407	0.00192	CcSEcCtD
Sorafenib—RET—brain—Alzheimer's disease	0.000406	0.00331	CbGeAlD
Sorafenib—Shock—Galantamine—Alzheimer's disease	0.000404	0.00191	CcSEcCtD
Sorafenib—Nervous system disorder—Galantamine—Alzheimer's disease	0.000403	0.0019	CcSEcCtD
Sorafenib—Thrombocytopenia—Galantamine—Alzheimer's disease	0.000403	0.0019	CcSEcCtD
Sorafenib—Urinary tract disorder—Memantine—Alzheimer's disease	0.000402	0.0019	CcSEcCtD
Sorafenib—Arrhythmia—Donepezil—Alzheimer's disease	0.000401	0.00189	CcSEcCtD
Sorafenib—Haemoglobin—Rivastigmine—Alzheimer's disease	0.0004	0.00189	CcSEcCtD
Sorafenib—Connective tissue disorder—Memantine—Alzheimer's disease	0.0004	0.00189	CcSEcCtD
Sorafenib—Skin disorder—Galantamine—Alzheimer's disease	0.000399	0.00188	CcSEcCtD
Sorafenib—Urethral disorder—Memantine—Alzheimer's disease	0.000399	0.00188	CcSEcCtD
Sorafenib—Haemorrhage—Rivastigmine—Alzheimer's disease	0.000398	0.00188	CcSEcCtD
Sorafenib—Alopecia—Donepezil—Alzheimer's disease	0.000396	0.00187	CcSEcCtD
Sorafenib—MAP2K5—nervous system—Alzheimer's disease	0.000396	0.00323	CbGeAlD
Sorafenib—KDR—nervous system—Alzheimer's disease	0.000396	0.00323	CbGeAlD
Sorafenib—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.000393	0.00186	CcSEcCtD
Sorafenib—Mental disorder—Donepezil—Alzheimer's disease	0.000393	0.00185	CcSEcCtD
Sorafenib—Anorexia—Galantamine—Alzheimer's disease	0.000392	0.00185	CcSEcCtD
Sorafenib—Connective tissue disorder—Rivastigmine—Alzheimer's disease	0.000391	0.00185	CcSEcCtD
Sorafenib—Urethral disorder—Rivastigmine—Alzheimer's disease	0.00039	0.00184	CcSEcCtD
Sorafenib—Erythema—Donepezil—Alzheimer's disease	0.00039	0.00184	CcSEcCtD
Sorafenib—Malnutrition—Donepezil—Alzheimer's disease	0.00039	0.00184	CcSEcCtD
Sorafenib—CSF1R—nervous system—Alzheimer's disease	0.000386	0.00315	CbGeAlD
Sorafenib—Erythema multiforme—Memantine—Alzheimer's disease	0.000385	0.00182	CcSEcCtD
Sorafenib—Dysgeusia—Donepezil—Alzheimer's disease	0.000382	0.0018	CcSEcCtD
Sorafenib—KDR—central nervous system—Alzheimer's disease	0.000381	0.00311	CbGeAlD
Sorafenib—MAP2K5—central nervous system—Alzheimer's disease	0.000381	0.00311	CbGeAlD
Sorafenib—Tinnitus—Memantine—Alzheimer's disease	0.00038	0.00179	CcSEcCtD
Sorafenib—Cardiac disorder—Memantine—Alzheimer's disease	0.000378	0.00178	CcSEcCtD
Sorafenib—Flushing—Memantine—Alzheimer's disease	0.000378	0.00178	CcSEcCtD
Sorafenib—Erythema multiforme—Rivastigmine—Alzheimer's disease	0.000377	0.00178	CcSEcCtD
Sorafenib—RALBP1—brain—Alzheimer's disease	0.000376	0.00307	CbGeAlD
Sorafenib—Muscle spasms—Donepezil—Alzheimer's disease	0.000375	0.00177	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000375	0.00177	CcSEcCtD
Sorafenib—KDR—cerebellum—Alzheimer's disease	0.000373	0.00303	CbGeAlD
Sorafenib—MAP2K5—cerebellum—Alzheimer's disease	0.000373	0.00303	CbGeAlD
Sorafenib—CSF1R—central nervous system—Alzheimer's disease	0.000372	0.00303	CbGeAlD
Sorafenib—Tinnitus—Rivastigmine—Alzheimer's disease	0.000371	0.00175	CcSEcCtD
Sorafenib—Flushing—Rivastigmine—Alzheimer's disease	0.00037	0.00174	CcSEcCtD
Sorafenib—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.00037	0.00174	CcSEcCtD
Sorafenib—Angiopathy—Memantine—Alzheimer's disease	0.000369	0.00174	CcSEcCtD
Sorafenib—Immune system disorder—Memantine—Alzheimer's disease	0.000368	0.00174	CcSEcCtD
Sorafenib—Mediastinal disorder—Memantine—Alzheimer's disease	0.000367	0.00173	CcSEcCtD
Sorafenib—Arrhythmia—Memantine—Alzheimer's disease	0.000364	0.00172	CcSEcCtD
Sorafenib—CSF1R—cerebellum—Alzheimer's disease	0.000364	0.00296	CbGeAlD
Sorafenib—Dyspepsia—Galantamine—Alzheimer's disease	0.000362	0.00171	CcSEcCtD
Sorafenib—Angiopathy—Rivastigmine—Alzheimer's disease	0.000361	0.00171	CcSEcCtD
Sorafenib—Anaemia—Donepezil—Alzheimer's disease	0.000361	0.0017	CcSEcCtD
Sorafenib—Alopecia—Memantine—Alzheimer's disease	0.00036	0.0017	CcSEcCtD
Sorafenib—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000359	0.00169	CcSEcCtD
Sorafenib—FLT1—brain—Alzheimer's disease	0.000358	0.00292	CbGeAlD
Sorafenib—Decreased appetite—Galantamine—Alzheimer's disease	0.000357	0.00169	CcSEcCtD
Sorafenib—Mental disorder—Memantine—Alzheimer's disease	0.000357	0.00168	CcSEcCtD
Sorafenib—Arrhythmia—Rivastigmine—Alzheimer's disease	0.000356	0.00168	CcSEcCtD
Sorafenib—RAF1—brain—Alzheimer's disease	0.000356	0.0029	CbGeAlD
Sorafenib—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000355	0.00167	CcSEcCtD
Sorafenib—Malnutrition—Memantine—Alzheimer's disease	0.000354	0.00167	CcSEcCtD
Sorafenib—Fatigue—Galantamine—Alzheimer's disease	0.000354	0.00167	CcSEcCtD
Sorafenib—EPHB6—brain—Alzheimer's disease	0.000354	0.00288	CbGeAlD
Sorafenib—Alopecia—Rivastigmine—Alzheimer's disease	0.000352	0.00166	CcSEcCtD
Sorafenib—Constipation—Galantamine—Alzheimer's disease	0.000352	0.00166	CcSEcCtD
Sorafenib—KIT—nervous system—Alzheimer's disease	0.000351	0.00286	CbGeAlD
Sorafenib—Syncope—Donepezil—Alzheimer's disease	0.00035	0.00165	CcSEcCtD
Sorafenib—Mental disorder—Rivastigmine—Alzheimer's disease	0.000349	0.00165	CcSEcCtD
Sorafenib—Dysgeusia—Memantine—Alzheimer's disease	0.000347	0.00164	CcSEcCtD
Sorafenib—Erythema—Rivastigmine—Alzheimer's disease	0.000347	0.00164	CcSEcCtD
Sorafenib—Malnutrition—Rivastigmine—Alzheimer's disease	0.000347	0.00164	CcSEcCtD
Sorafenib—Loss of consciousness—Donepezil—Alzheimer's disease	0.000343	0.00162	CcSEcCtD
Sorafenib—PDGFRB—nervous system—Alzheimer's disease	0.000343	0.00279	CbGeAlD
Sorafenib—Cough—Donepezil—Alzheimer's disease	0.000341	0.00161	CcSEcCtD
Sorafenib—Dysgeusia—Rivastigmine—Alzheimer's disease	0.00034	0.0016	CcSEcCtD
Sorafenib—STK10—brain—Alzheimer's disease	0.000339	0.00276	CbGeAlD
Sorafenib—KIT—central nervous system—Alzheimer's disease	0.000338	0.00275	CbGeAlD
Sorafenib—Hypertension—Donepezil—Alzheimer's disease	0.000337	0.00159	CcSEcCtD
Sorafenib—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000336	0.00159	CcSEcCtD
Sorafenib—PDGFRA—brain—Alzheimer's disease	0.000335	0.00273	CbGeAlD
Sorafenib—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000333	0.00157	CcSEcCtD
Sorafenib—Myalgia—Donepezil—Alzheimer's disease	0.000332	0.00157	CcSEcCtD
Sorafenib—Arthralgia—Donepezil—Alzheimer's disease	0.000332	0.00157	CcSEcCtD
Sorafenib—ABCB1—blood vessel—Alzheimer's disease	0.000332	0.0027	CbGeAlD
Sorafenib—KIT—cerebellum—Alzheimer's disease	0.00033	0.00269	CbGeAlD
Sorafenib—PDGFRB—central nervous system—Alzheimer's disease	0.00033	0.00269	CbGeAlD
Sorafenib—Anaemia—Memantine—Alzheimer's disease	0.000328	0.00155	CcSEcCtD
Sorafenib—ABCG2—telencephalon—Alzheimer's disease	0.000326	0.00266	CbGeAlD
Sorafenib—Dry mouth—Donepezil—Alzheimer's disease	0.000325	0.00153	CcSEcCtD
Sorafenib—Abdominal pain—Galantamine—Alzheimer's disease	0.000325	0.00153	CcSEcCtD
Sorafenib—Body temperature increased—Galantamine—Alzheimer's disease	0.000325	0.00153	CcSEcCtD
Sorafenib—PDGFRB—cerebellum—Alzheimer's disease	0.000322	0.00263	CbGeAlD
Sorafenib—Anaemia—Rivastigmine—Alzheimer's disease	0.000321	0.00151	CcSEcCtD
Sorafenib—Syncope—Memantine—Alzheimer's disease	0.000318	0.0015	CcSEcCtD
Sorafenib—Leukopenia—Memantine—Alzheimer's disease	0.000317	0.0015	CcSEcCtD
Sorafenib—Infection—Donepezil—Alzheimer's disease	0.000317	0.00149	CcSEcCtD
Sorafenib—Shock—Donepezil—Alzheimer's disease	0.000313	0.00148	CcSEcCtD
Sorafenib—Nervous system disorder—Donepezil—Alzheimer's disease	0.000312	0.00147	CcSEcCtD
Sorafenib—Thrombocytopenia—Donepezil—Alzheimer's disease	0.000312	0.00147	CcSEcCtD
Sorafenib—Loss of consciousness—Memantine—Alzheimer's disease	0.000312	0.00147	CcSEcCtD
Sorafenib—Syncope—Rivastigmine—Alzheimer's disease	0.000311	0.00147	CcSEcCtD
Sorafenib—Cough—Memantine—Alzheimer's disease	0.000309	0.00146	CcSEcCtD
Sorafenib—Hypertension—Memantine—Alzheimer's disease	0.000306	0.00144	CcSEcCtD
Sorafenib—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000305	0.00144	CcSEcCtD
Sorafenib—Anorexia—Donepezil—Alzheimer's disease	0.000304	0.00143	CcSEcCtD
Sorafenib—Hypersensitivity—Galantamine—Alzheimer's disease	0.000303	0.00143	CcSEcCtD
Sorafenib—Cough—Rivastigmine—Alzheimer's disease	0.000303	0.00143	CcSEcCtD
Sorafenib—KDR—brain—Alzheimer's disease	0.000303	0.00247	CbGeAlD
Sorafenib—MAP2K5—brain—Alzheimer's disease	0.000303	0.00247	CbGeAlD
Sorafenib—Myalgia—Memantine—Alzheimer's disease	0.000302	0.00142	CcSEcCtD
Sorafenib—Arthralgia—Memantine—Alzheimer's disease	0.000302	0.00142	CcSEcCtD
Sorafenib—Hypertension—Rivastigmine—Alzheimer's disease	0.000299	0.00141	CcSEcCtD
Sorafenib—CSF1R—brain—Alzheimer's disease	0.000295	0.00241	CbGeAlD
Sorafenib—Myalgia—Rivastigmine—Alzheimer's disease	0.000295	0.00139	CcSEcCtD
Sorafenib—Arthralgia—Rivastigmine—Alzheimer's disease	0.000295	0.00139	CcSEcCtD
Sorafenib—Dry mouth—Memantine—Alzheimer's disease	0.000295	0.00139	CcSEcCtD
Sorafenib—Asthenia—Galantamine—Alzheimer's disease	0.000295	0.00139	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.000293	0.00138	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.00029	0.00137	CcSEcCtD
Sorafenib—HTR2C—nervous system—Alzheimer's disease	0.000289	0.00235	CbGeAlD
Sorafenib—Dry mouth—Rivastigmine—Alzheimer's disease	0.000289	0.00136	CcSEcCtD
Sorafenib—Infection—Memantine—Alzheimer's disease	0.000287	0.00136	CcSEcCtD
Sorafenib—Shock—Memantine—Alzheimer's disease	0.000285	0.00134	CcSEcCtD
Sorafenib—Dyspnoea—Donepezil—Alzheimer's disease	0.000284	0.00134	CcSEcCtD
Sorafenib—Nervous system disorder—Memantine—Alzheimer's disease	0.000284	0.00134	CcSEcCtD
Sorafenib—Thrombocytopenia—Memantine—Alzheimer's disease	0.000283	0.00134	CcSEcCtD
Sorafenib—Diarrhoea—Galantamine—Alzheimer's disease	0.000281	0.00133	CcSEcCtD
Sorafenib—Infection—Rivastigmine—Alzheimer's disease	0.000281	0.00133	CcSEcCtD
Sorafenib—Skin disorder—Memantine—Alzheimer's disease	0.000281	0.00133	CcSEcCtD
Sorafenib—Dyspepsia—Donepezil—Alzheimer's disease	0.00028	0.00132	CcSEcCtD
Sorafenib—Shock—Rivastigmine—Alzheimer's disease	0.000278	0.00131	CcSEcCtD
Sorafenib—HTR2C—central nervous system—Alzheimer's disease	0.000278	0.00227	CbGeAlD
Sorafenib—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.000278	0.00131	CcSEcCtD
Sorafenib—Thrombocytopenia—Rivastigmine—Alzheimer's disease	0.000277	0.00131	CcSEcCtD
Sorafenib—Decreased appetite—Donepezil—Alzheimer's disease	0.000277	0.00131	CcSEcCtD
Sorafenib—Anorexia—Memantine—Alzheimer's disease	0.000276	0.0013	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000275	0.0013	CcSEcCtD
Sorafenib—Skin disorder—Rivastigmine—Alzheimer's disease	0.000275	0.0013	CcSEcCtD
Sorafenib—Fatigue—Donepezil—Alzheimer's disease	0.000275	0.0013	CcSEcCtD
Sorafenib—ABCC4—nervous system—Alzheimer's disease	0.000273	0.00222	CbGeAlD
Sorafenib—Constipation—Donepezil—Alzheimer's disease	0.000272	0.00129	CcSEcCtD
Sorafenib—Pain—Donepezil—Alzheimer's disease	0.000272	0.00129	CcSEcCtD
Sorafenib—Dizziness—Galantamine—Alzheimer's disease	0.000272	0.00128	CcSEcCtD
Sorafenib—HTR2B—nervous system—Alzheimer's disease	0.000271	0.00221	CbGeAlD
Sorafenib—Anorexia—Rivastigmine—Alzheimer's disease	0.00027	0.00127	CcSEcCtD
Sorafenib—KIT—brain—Alzheimer's disease	0.000268	0.00218	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000264	0.00124	CcSEcCtD
Sorafenib—ABCC4—central nervous system—Alzheimer's disease	0.000263	0.00214	CbGeAlD
Sorafenib—PDGFRB—brain—Alzheimer's disease	0.000262	0.00213	CbGeAlD
Sorafenib—Vomiting—Galantamine—Alzheimer's disease	0.000261	0.00123	CcSEcCtD
Sorafenib—HTR2B—central nervous system—Alzheimer's disease	0.000261	0.00213	CbGeAlD
Sorafenib—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.000261	0.00123	CcSEcCtD
Sorafenib—Rash—Galantamine—Alzheimer's disease	0.000259	0.00122	CcSEcCtD
Sorafenib—Dermatitis—Galantamine—Alzheimer's disease	0.000259	0.00122	CcSEcCtD
Sorafenib—Dyspnoea—Memantine—Alzheimer's disease	0.000258	0.00122	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.000258	0.00122	CcSEcCtD
Sorafenib—Headache—Galantamine—Alzheimer's disease	0.000258	0.00122	CcSEcCtD
Sorafenib—Dyspepsia—Memantine—Alzheimer's disease	0.000255	0.0012	CcSEcCtD
Sorafenib—Urticaria—Donepezil—Alzheimer's disease	0.000253	0.00119	CcSEcCtD
Sorafenib—Dyspnoea—Rivastigmine—Alzheimer's disease	0.000252	0.00119	CcSEcCtD
Sorafenib—Body temperature increased—Donepezil—Alzheimer's disease	0.000252	0.00119	CcSEcCtD
Sorafenib—Abdominal pain—Donepezil—Alzheimer's disease	0.000252	0.00119	CcSEcCtD
Sorafenib—Decreased appetite—Memantine—Alzheimer's disease	0.000251	0.00119	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.00025	0.00118	CcSEcCtD
Sorafenib—Fatigue—Memantine—Alzheimer's disease	0.000249	0.00118	CcSEcCtD
Sorafenib—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000249	0.00118	CcSEcCtD
Sorafenib—Pain—Memantine—Alzheimer's disease	0.000247	0.00117	CcSEcCtD
Sorafenib—Constipation—Memantine—Alzheimer's disease	0.000247	0.00117	CcSEcCtD
Sorafenib—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000246	0.00116	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000244	0.00115	CcSEcCtD
Sorafenib—Nausea—Galantamine—Alzheimer's disease	0.000244	0.00115	CcSEcCtD
Sorafenib—Fatigue—Rivastigmine—Alzheimer's disease	0.000244	0.00115	CcSEcCtD
Sorafenib—CYP2D6—forebrain—Alzheimer's disease	0.000243	0.00198	CbGeAlD
Sorafenib—Pain—Rivastigmine—Alzheimer's disease	0.000242	0.00114	CcSEcCtD
Sorafenib—Constipation—Rivastigmine—Alzheimer's disease	0.000242	0.00114	CcSEcCtD
Sorafenib—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000237	0.00112	CcSEcCtD
Sorafenib—Hypersensitivity—Donepezil—Alzheimer's disease	0.000235	0.00111	CcSEcCtD
Sorafenib—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.000231	0.00109	CcSEcCtD
Sorafenib—Urticaria—Memantine—Alzheimer's disease	0.00023	0.00108	CcSEcCtD
Sorafenib—Abdominal pain—Memantine—Alzheimer's disease	0.000229	0.00108	CcSEcCtD
Sorafenib—Body temperature increased—Memantine—Alzheimer's disease	0.000229	0.00108	CcSEcCtD
Sorafenib—Asthenia—Donepezil—Alzheimer's disease	0.000229	0.00108	CcSEcCtD
Sorafenib—Pruritus—Donepezil—Alzheimer's disease	0.000225	0.00106	CcSEcCtD
Sorafenib—Urticaria—Rivastigmine—Alzheimer's disease	0.000225	0.00106	CcSEcCtD
Sorafenib—Abdominal pain—Rivastigmine—Alzheimer's disease	0.000224	0.00106	CcSEcCtD
Sorafenib—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000224	0.00106	CcSEcCtD
Sorafenib—CYP2D6—telencephalon—Alzheimer's disease	0.000224	0.00182	CbGeAlD
Sorafenib—HTR2C—brain—Alzheimer's disease	0.000221	0.0018	CbGeAlD
Sorafenib—Diarrhoea—Donepezil—Alzheimer's disease	0.000218	0.00103	CcSEcCtD
Sorafenib—Hypersensitivity—Memantine—Alzheimer's disease	0.000213	0.00101	CcSEcCtD
Sorafenib—Dizziness—Donepezil—Alzheimer's disease	0.000211	0.000994	CcSEcCtD
Sorafenib—ABCC4—brain—Alzheimer's disease	0.000209	0.0017	CbGeAlD
Sorafenib—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.000209	0.000984	CcSEcCtD
Sorafenib—Asthenia—Memantine—Alzheimer's disease	0.000208	0.000979	CcSEcCtD
Sorafenib—HTR2B—brain—Alzheimer's disease	0.000207	0.00169	CbGeAlD
Sorafenib—Pruritus—Memantine—Alzheimer's disease	0.000205	0.000966	CcSEcCtD
Sorafenib—Asthenia—Rivastigmine—Alzheimer's disease	0.000203	0.000958	CcSEcCtD
Sorafenib—Vomiting—Donepezil—Alzheimer's disease	0.000203	0.000956	CcSEcCtD
Sorafenib—Rash—Donepezil—Alzheimer's disease	0.000201	0.000948	CcSEcCtD
Sorafenib—Dermatitis—Donepezil—Alzheimer's disease	0.000201	0.000947	CcSEcCtD
Sorafenib—Pruritus—Rivastigmine—Alzheimer's disease	0.0002	0.000945	CcSEcCtD
Sorafenib—Headache—Donepezil—Alzheimer's disease	0.0002	0.000942	CcSEcCtD
Sorafenib—Diarrhoea—Memantine—Alzheimer's disease	0.000198	0.000934	CcSEcCtD
Sorafenib—ABCB1—embryo—Alzheimer's disease	0.000198	0.00161	CbGeAlD
Sorafenib—Diarrhoea—Rivastigmine—Alzheimer's disease	0.000194	0.000914	CcSEcCtD
Sorafenib—Dizziness—Memantine—Alzheimer's disease	0.000191	0.000903	CcSEcCtD
Sorafenib—Nausea—Donepezil—Alzheimer's disease	0.000189	0.000893	CcSEcCtD
Sorafenib—Dizziness—Rivastigmine—Alzheimer's disease	0.000187	0.000883	CcSEcCtD
Sorafenib—Vomiting—Memantine—Alzheimer's disease	0.000184	0.000868	CcSEcCtD
Sorafenib—Rash—Memantine—Alzheimer's disease	0.000182	0.000861	CcSEcCtD
Sorafenib—Dermatitis—Memantine—Alzheimer's disease	0.000182	0.00086	CcSEcCtD
Sorafenib—Headache—Memantine—Alzheimer's disease	0.000181	0.000855	CcSEcCtD
Sorafenib—ABCG2—cerebellum—Alzheimer's disease	0.000181	0.00148	CbGeAlD
Sorafenib—Vomiting—Rivastigmine—Alzheimer's disease	0.00018	0.000849	CcSEcCtD
Sorafenib—Rash—Rivastigmine—Alzheimer's disease	0.000178	0.000842	CcSEcCtD
Sorafenib—Dermatitis—Rivastigmine—Alzheimer's disease	0.000178	0.000841	CcSEcCtD
Sorafenib—CYP2B6—nervous system—Alzheimer's disease	0.000178	0.00145	CbGeAlD
Sorafenib—Headache—Rivastigmine—Alzheimer's disease	0.000177	0.000837	CcSEcCtD
Sorafenib—ABCB1—forebrain—Alzheimer's disease	0.000175	0.00143	CbGeAlD
Sorafenib—Nausea—Memantine—Alzheimer's disease	0.000172	0.000811	CcSEcCtD
Sorafenib—CYP2B6—central nervous system—Alzheimer's disease	0.000171	0.00139	CbGeAlD
Sorafenib—Nausea—Rivastigmine—Alzheimer's disease	0.000168	0.000793	CcSEcCtD
Sorafenib—ABCB1—telencephalon—Alzheimer's disease	0.000161	0.00131	CbGeAlD
Sorafenib—CYP2C8—brain—Alzheimer's disease	0.000151	0.00123	CbGeAlD
Sorafenib—ABCG2—brain—Alzheimer's disease	0.000147	0.0012	CbGeAlD
Sorafenib—CYP2B6—brain—Alzheimer's disease	0.000136	0.00111	CbGeAlD
Sorafenib—CYP3A4—nervous system—Alzheimer's disease	0.000134	0.00109	CbGeAlD
Sorafenib—CYP2D6—nervous system—Alzheimer's disease	0.000132	0.00108	CbGeAlD
Sorafenib—CYP3A4—central nervous system—Alzheimer's disease	0.000129	0.00105	CbGeAlD
Sorafenib—CYP2D6—central nervous system—Alzheimer's disease	0.000127	0.00104	CbGeAlD
Sorafenib—CYP2D6—cerebellum—Alzheimer's disease	0.000124	0.00101	CbGeAlD
Sorafenib—CYP2D6—brain—Alzheimer's disease	0.000101	0.000822	CbGeAlD
Sorafenib—ABCB1—nervous system—Alzheimer's disease	9.5e-05	0.000774	CbGeAlD
Sorafenib—ABCB1—central nervous system—Alzheimer's disease	9.14e-05	0.000745	CbGeAlD
Sorafenib—ABCB1—cerebellum—Alzheimer's disease	8.94e-05	0.000728	CbGeAlD
Sorafenib—ABCB1—brain—Alzheimer's disease	7.26e-05	0.000591	CbGeAlD
Sorafenib—MAP3K7—Signaling Pathways—CASP3—Alzheimer's disease	2.36e-06	1.09e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	2.35e-06	1.08e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PLCB1—Alzheimer's disease	2.33e-06	1.07e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IGF1—Alzheimer's disease	2.33e-06	1.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ESR1—Alzheimer's disease	2.32e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MTHFR—Alzheimer's disease	2.31e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MAOB—Alzheimer's disease	2.31e-06	1.06e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—F2—Alzheimer's disease	2.29e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	2.28e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	2.27e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS1—Alzheimer's disease	2.27e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ENO1—Alzheimer's disease	2.27e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MTHFR—Alzheimer's disease	2.26e-06	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—Alzheimer's disease	2.26e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCA1—Alzheimer's disease	2.25e-06	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOTCH1—Alzheimer's disease	2.24e-06	1.03e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CASP3—Alzheimer's disease	2.24e-06	1.03e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—Alzheimer's disease	2.23e-06	1.03e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CASP3—Alzheimer's disease	2.23e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP2D6—Alzheimer's disease	2.22e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GAPDH—Alzheimer's disease	2.22e-06	1.02e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—Alzheimer's disease	2.22e-06	1.02e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—Alzheimer's disease	2.2e-06	1.01e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—Alzheimer's disease	2.2e-06	1.01e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AKT1—Alzheimer's disease	2.19e-06	1.01e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—Alzheimer's disease	2.18e-06	1.01e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—AKT1—Alzheimer's disease	2.18e-06	1e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—LPL—Alzheimer's disease	2.17e-06	1e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—Alzheimer's disease	2.17e-06	1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK8—Alzheimer's disease	2.17e-06	9.98e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK8—Alzheimer's disease	2.17e-06	9.98e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CALM1—Alzheimer's disease	2.16e-06	9.96e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—APOE—Alzheimer's disease	2.15e-06	9.92e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—A2M—Alzheimer's disease	2.15e-06	9.89e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—Alzheimer's disease	2.14e-06	9.86e-06	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—Alzheimer's disease	2.14e-06	9.86e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CAV1—Alzheimer's disease	2.13e-06	9.83e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARGC1A—Alzheimer's disease	2.13e-06	9.83e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—HMOX1—Alzheimer's disease	2.12e-06	9.78e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CALM1—Alzheimer's disease	2.11e-06	9.73e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—Alzheimer's disease	2.11e-06	9.72e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—BCHE—Alzheimer's disease	2.11e-06	9.71e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—GSK3B—Alzheimer's disease	2.1e-06	9.7e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—APOE—Alzheimer's disease	2.1e-06	9.7e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CREB1—Alzheimer's disease	2.09e-06	9.62e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CAV1—Alzheimer's disease	2.08e-06	9.61e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARGC1A—Alzheimer's disease	2.08e-06	9.59e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—INS—Alzheimer's disease	2.08e-06	9.57e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—HMOX1—Alzheimer's disease	2.07e-06	9.55e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK8—Alzheimer's disease	2.05e-06	9.47e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK8—Alzheimer's disease	2.05e-06	9.45e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—Alzheimer's disease	2.04e-06	9.42e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—Alzheimer's disease	2.03e-06	9.38e-06	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—Alzheimer's disease	2.03e-06	9.36e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—Alzheimer's disease	2.02e-06	9.33e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—Alzheimer's disease	2.02e-06	9.29e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—Alzheimer's disease	2.01e-06	9.28e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CASP3—Alzheimer's disease	2.01e-06	9.26e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF1—Alzheimer's disease	2.01e-06	9.26e-06	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—Alzheimer's disease	2e-06	9.22e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—Alzheimer's disease	2e-06	9.22e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—Alzheimer's disease	2e-06	9.22e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—Alzheimer's disease	2e-06	9.22e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—Alzheimer's disease	1.99e-06	9.19e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—Alzheimer's disease	1.99e-06	9.18e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PLCB1—Alzheimer's disease	1.99e-06	9.16e-06	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—Alzheimer's disease	1.97e-06	9.1e-06	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—Alzheimer's disease	1.97e-06	9.09e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—Alzheimer's disease	1.97e-06	9.09e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	1.96e-06	9.04e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—Alzheimer's disease	1.96e-06	9.02e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	1.95e-06	9e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	1.95e-06	8.99e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—Alzheimer's disease	1.95e-06	8.98e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARGC1A—Alzheimer's disease	1.94e-06	8.96e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—LPL—Alzheimer's disease	1.94e-06	8.95e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HMOX1—Alzheimer's disease	1.93e-06	8.92e-06	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—Alzheimer's disease	1.93e-06	8.91e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCA1—Alzheimer's disease	1.93e-06	8.88e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CASP3—Alzheimer's disease	1.92e-06	8.83e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—Alzheimer's disease	1.9e-06	8.77e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—Alzheimer's disease	1.9e-06	8.75e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—LPL—Alzheimer's disease	1.89e-06	8.73e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—Alzheimer's disease	1.89e-06	8.72e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—Alzheimer's disease	1.87e-06	8.64e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—Alzheimer's disease	1.87e-06	8.64e-06	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—Alzheimer's disease	1.87e-06	8.63e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—Alzheimer's disease	1.87e-06	8.62e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—Alzheimer's disease	1.87e-06	8.61e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ACHE—Alzheimer's disease	1.87e-06	8.6e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK8—Alzheimer's disease	1.85e-06	8.51e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INPP5D—Alzheimer's disease	1.84e-06	8.51e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—INS—Alzheimer's disease	1.84e-06	8.48e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—Alzheimer's disease	1.83e-06	8.46e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—Alzheimer's disease	1.83e-06	8.46e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—Alzheimer's disease	1.83e-06	8.45e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—Alzheimer's disease	1.83e-06	8.44e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CALM1—Alzheimer's disease	1.83e-06	8.43e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—Alzheimer's disease	1.82e-06	8.41e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—Alzheimer's disease	1.82e-06	8.4e-06	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—Alzheimer's disease	1.82e-06	8.4e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—Alzheimer's disease	1.82e-06	8.39e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CAV1—Alzheimer's disease	1.81e-06	8.32e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—INS—Alzheimer's disease	1.8e-06	8.29e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—Alzheimer's disease	1.79e-06	8.25e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—LPL—Alzheimer's disease	1.78e-06	8.23e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—Alzheimer's disease	1.78e-06	8.22e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—Alzheimer's disease	1.78e-06	8.2e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—LPL—Alzheimer's disease	1.77e-06	8.16e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK8—Alzheimer's disease	1.76e-06	8.12e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—Alzheimer's disease	1.76e-06	8.1e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO1—Alzheimer's disease	1.75e-06	8.06e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS1—Alzheimer's disease	1.75e-06	8.06e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—Alzheimer's disease	1.75e-06	8.06e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—Alzheimer's disease	1.74e-06	8.03e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—Alzheimer's disease	1.74e-06	8.01e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—Alzheimer's disease	1.73e-06	7.97e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—Alzheimer's disease	1.72e-06	7.95e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2D6—Alzheimer's disease	1.72e-06	7.91e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—Alzheimer's disease	1.71e-06	7.86e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—Alzheimer's disease	1.7e-06	7.86e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—Alzheimer's disease	1.69e-06	7.78e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—Alzheimer's disease	1.68e-06	7.76e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—Alzheimer's disease	1.68e-06	7.76e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—Alzheimer's disease	1.68e-06	7.72e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARGC1A—Alzheimer's disease	1.66e-06	7.66e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—Alzheimer's disease	1.66e-06	7.65e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—Alzheimer's disease	1.65e-06	7.62e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK8—Alzheimer's disease	1.65e-06	7.59e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—Alzheimer's disease	1.64e-06	7.58e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—Alzheimer's disease	1.64e-06	7.57e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CALM1—Alzheimer's disease	1.63e-06	7.53e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—Alzheimer's disease	1.63e-06	7.5e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—BCHE—Alzheimer's disease	1.63e-06	7.5e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—Alzheimer's disease	1.63e-06	7.49e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—Alzheimer's disease	1.63e-06	7.49e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—Alzheimer's disease	1.61e-06	7.43e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAV1—Alzheimer's disease	1.61e-06	7.43e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	1.61e-06	7.41e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CALM1—Alzheimer's disease	1.59e-06	7.35e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—Alzheimer's disease	1.59e-06	7.34e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—Alzheimer's disease	1.59e-06	7.32e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—Alzheimer's disease	1.59e-06	7.32e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—Alzheimer's disease	1.58e-06	7.27e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAV1—Alzheimer's disease	1.57e-06	7.25e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—Alzheimer's disease	1.56e-06	7.21e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—Alzheimer's disease	1.56e-06	7.19e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INS—Alzheimer's disease	1.56e-06	7.18e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—Alzheimer's disease	1.55e-06	7.16e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—Alzheimer's disease	1.55e-06	7.13e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—Alzheimer's disease	1.54e-06	7.08e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PLCB1—Alzheimer's disease	1.53e-06	7.07e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—Alzheimer's disease	1.53e-06	7.07e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—Alzheimer's disease	1.52e-06	7e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—Alzheimer's disease	1.52e-06	7e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—LPL—Alzheimer's disease	1.51e-06	6.97e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—Alzheimer's disease	1.51e-06	6.96e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—Alzheimer's disease	1.51e-06	6.96e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CALM1—Alzheimer's disease	1.5e-06	6.92e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—Alzheimer's disease	1.5e-06	6.92e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—Alzheimer's disease	1.5e-06	6.91e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—Alzheimer's disease	1.5e-06	6.9e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—Alzheimer's disease	1.49e-06	6.88e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CALM1—Alzheimer's disease	1.49e-06	6.86e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCA1—Alzheimer's disease	1.49e-06	6.86e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—Alzheimer's disease	1.48e-06	6.84e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAV1—Alzheimer's disease	1.48e-06	6.83e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—Alzheimer's disease	1.47e-06	6.8e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAV1—Alzheimer's disease	1.47e-06	6.77e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—Alzheimer's disease	1.44e-06	6.65e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—Alzheimer's disease	1.43e-06	6.61e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—Alzheimer's disease	1.43e-06	6.59e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK8—Alzheimer's disease	1.42e-06	6.55e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—Alzheimer's disease	1.42e-06	6.53e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—Alzheimer's disease	1.42e-06	6.53e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—Alzheimer's disease	1.41e-06	6.52e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—Alzheimer's disease	1.4e-06	6.46e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—Alzheimer's disease	1.39e-06	6.43e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INS—Alzheimer's disease	1.39e-06	6.41e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—Alzheimer's disease	1.38e-06	6.38e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—Alzheimer's disease	1.38e-06	6.38e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—Alzheimer's disease	1.38e-06	6.37e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—Alzheimer's disease	1.38e-06	6.37e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—Alzheimer's disease	1.37e-06	6.29e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—Alzheimer's disease	1.36e-06	6.28e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INS—Alzheimer's disease	1.36e-06	6.25e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—Alzheimer's disease	1.31e-06	6.05e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—Alzheimer's disease	1.31e-06	6.05e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—Alzheimer's disease	1.31e-06	6.03e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—Alzheimer's disease	1.3e-06	6.01e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—Alzheimer's disease	1.29e-06	5.96e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—Alzheimer's disease	1.29e-06	5.94e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARGC1A—Alzheimer's disease	1.28e-06	5.91e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INS—Alzheimer's disease	1.28e-06	5.89e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—Alzheimer's disease	1.28e-06	5.88e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—Alzheimer's disease	1.28e-06	5.88e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—Alzheimer's disease	1.28e-06	5.88e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CALM1—Alzheimer's disease	1.27e-06	5.86e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—Alzheimer's disease	1.27e-06	5.84e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INS—Alzheimer's disease	1.27e-06	5.84e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAV1—Alzheimer's disease	1.26e-06	5.79e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—Alzheimer's disease	1.25e-06	5.76e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—Alzheimer's disease	1.23e-06	5.66e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—Alzheimer's disease	1.22e-06	5.62e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—Alzheimer's disease	1.21e-06	5.58e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—Alzheimer's disease	1.21e-06	5.57e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—Alzheimer's disease	1.2e-06	5.55e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—Alzheimer's disease	1.19e-06	5.49e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—Alzheimer's disease	1.19e-06	5.49e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—Alzheimer's disease	1.19e-06	5.48e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—Alzheimer's disease	1.18e-06	5.44e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LPL—Alzheimer's disease	1.17e-06	5.38e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—Alzheimer's disease	1.15e-06	5.29e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—Alzheimer's disease	1.12e-06	5.18e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—Alzheimer's disease	1.12e-06	5.17e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—Alzheimer's disease	1.11e-06	5.14e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—Alzheimer's disease	1.11e-06	5.12e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—Alzheimer's disease	1.1e-06	5.09e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—Alzheimer's disease	1.09e-06	5.02e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—Alzheimer's disease	1.09e-06	5.01e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INS—Alzheimer's disease	1.08e-06	4.99e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—Alzheimer's disease	1.05e-06	4.84e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—Alzheimer's disease	1.05e-06	4.84e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—Alzheimer's disease	1.04e-06	4.78e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	1.03e-06	4.73e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—Alzheimer's disease	1.02e-06	4.69e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—Alzheimer's disease	1.01e-06	4.66e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—Alzheimer's disease	1e-06	4.62e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—Alzheimer's disease	9.91e-07	4.57e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CALM1—Alzheimer's disease	9.82e-07	4.53e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—Alzheimer's disease	9.78e-07	4.51e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—Alzheimer's disease	9.69e-07	4.47e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAV1—Alzheimer's disease	9.69e-07	4.47e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—Alzheimer's disease	9.5e-07	4.38e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—Alzheimer's disease	9.07e-07	4.18e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—Alzheimer's disease	8.68e-07	4e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—Alzheimer's disease	8.52e-07	3.93e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—Alzheimer's disease	8.37e-07	3.86e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INS—Alzheimer's disease	8.36e-07	3.85e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—Alzheimer's disease	7.41e-07	3.42e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—Alzheimer's disease	7.33e-07	3.38e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—Alzheimer's disease	7.25e-07	3.34e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—Alzheimer's disease	6.7e-07	3.09e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—Alzheimer's disease	6.28e-07	2.89e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—Alzheimer's disease	5.6e-07	2.58e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—Alzheimer's disease	5.47e-07	2.52e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—Alzheimer's disease	5.15e-07	2.38e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—Alzheimer's disease	5.11e-07	2.35e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—Alzheimer's disease	4.36e-07	2.01e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—Alzheimer's disease	3.37e-07	1.55e-06	CbGpPWpGaD
